Page 3 of 8, showing 50 records out of 368 total, starting on record 101, ending on 150
| Publication |
Category |
Year |
|
31. Labrie, F., Cusan, L., Gomez, J.L., Candas, B., Bélanger, A., Luu-The, V., Simard, J. (2003) De la biologie à la clinique: le décès dû au cancer de la prostate peut-il maintenant être une exception? Médecine/Sciences, 19: 910-19. |
Prostate Cancer |
2003 |
|
83. Labrie, F., Cusan, L., Gomez, J.L., Diamond, P., Bélanger, A., Candas, B. (1997) Long-term neoadjuvant and adjuvant combined androgen blockade is needed for efficacy of treatment in localized prostate cancer. Mol. Urol., 1: 253-261. |
Prostate Cancer |
1997 |
|
113. Labrie, F., Cusan, L., Gomez, J.L., Diamond, P., Candas, B. (1995) Combination of screening and preoperative endocrine therapy: the potential for an important decrease in prostate cancer mortality. J. Clin. Endocrinol. Metab., 80: 2002-2013. |
Prostate Cancer |
1995 |
|
114. Labrie, F., Cusan, L., Gomez, J.L., Diamond, P., Suburu, R., Lemay, M., Candas, B. (1995) Screening und Re-Screening des Prostatakarzinoms: Die Quebec-Studie, in Faul, P. et Altwein, J.E., eds: Screening des Prostatakarzinoms, Berlin, Springer-Verlag, pp 339-352. |
Prostate Cancer |
1995 |
|
84. Labrie, F., Cusan, L., Gomez, J.L., Diamond, P., Suburu, R., Lemay, M., Tetu, B., Fradet, Y., Bélanger, A., Candas, B. (1997) Neoadjuvant hormonal therapy: the Canadian experience. Urology, 49: 56-64. |
Prostate Cancer |
1997 |
|
128. Labrie, F., Cusan, L., Gomez, J.L., Diamond, P., Suburu, R., Lemay, M., Tetu, B., Fradet, Y., Candas, B. (1994) Downstaging of early stage prostate cancer before radical prostatectomy: the first randomized trial of neoadjuvant combination therapy with Flutamide and a luteinizing hormone-releasing hormone agonist. Urology, 44: 29-37. |
Prostate Cancer |
1994 |
|
115. Labrie, F., Cusan, L., Gomez, J.L., Diamond, P., Suburu, R., Lemay, M., Tetu, B., Fradet, Y., Candas, B. (1995) Downstaging by combination therapy with flutamide and an LHRH agonist before radical prostatectomy. Cancer Surv. 23: 149-156. |
Prostate Cancer |
1995 |
|
4692. Labrie, F., Cusan, L., Gomez, J.L., Martel, C., Bérubé, R., Bélanger, P., Bélanger, A., Vandenput, L., Mellström, D., Ohlsson, C. (2009) Comparable Amounts of Sex Steroids are Made Outside the Gonads in Men and Women: Strong Lesson for Hormone Therapy of Prostate and Breast Cancer, JSBMB, 113: 52-56. |
Prostate Cancer |
2009 |
|
173. Labrie, F., Dupont, A., Cusan, L., Gomez, J., Emond, J., Monfette, G. (1990) Combination therapy with Flutamide and medical (LHRH agonist) or surgical castration in advanced prostate cancer: 7-year clinical experience. J. Steroid Biochem. Mol. Biol., 37: 943-950. |
Prostate Cancer |
1990 |
|
150. Labrie, F., Dupont, A., Cusan, L., Gomez, J., Emond, J., Monfette, G. (1992) Combination therapy with Flutamide and medical (LHRH agonist) or surgical castration in advanced prostate cancer (8-year clinical experience) and extension to early stages of the diseases, in: Carpi, A., Sagripanti, A. et Mittermayer, eds: Progress in Clinical Oncology, Italy, Sympomed Verlag, pp 278-293. |
Prostate Cancer |
1992 |
|
142. Labrie, F., Dupont, A., Cusan, L., Gomez, J.L., Diamond, P., Koutsilieris, M., Suburu, R., Fradet, Y., Lemay, M., Tetu, B., Emond, J., Candas, B. (1993) Downstaging of localized prostate cancer by neoadjuvant therapy with Flutamide and Lupron. Clin. Invest. Med., 16: 499-509. |
Prostate Cancer |
1993 |
|
103. Labrie, F., Dupont, A., Cusan, L., Gomez, J.L., Surubu, R., Diamond, P. (1996) Combination therapy with Flutamide: The therapy of choice from early to advanced stages of prostate cancer, in: Denis, L., ed. Antiandrogens in Prostatic Cancer, Italy, European School of Oncology, pp 63-74. |
Prostate Cancer |
1996 |
|
151. Labrie, F., Dupont, A., Cusan, L., Suburu, E.R., Gomez, J.L., Thibault, M.M., Tremblay, M. (1992) Perspectives dans le diagnostic et le traitement du cancer de la prostate au stade précoce, in: Bonjour, J.P., Gayraud, M.,Guillevin, L. et Rizzoli, R., eds: Nouvelles statégies thérapeutiques en cancérologie, rapports présentés au XLVIIIe Congrès Français de Médecine, Montréal 1991, Alertes carcinologiques, pp 25-44. |
Prostate Cancer |
1992 |
|
143. Labrie, F., Dupont, A., Simard, J., Luu-The, V., Bélanger, A. (1993) Intracrinology: the basis for the rational design of endocrine therapy at all stages of prostate cancer. Eur. Urol., 24 Suppl. 2: 94-105. |
Prostate Cancer |
1993 |
|
144. Labrie, F., Dupont, A., Suburu, R., Cusan, L., Gomez, J.L., Koutsilieris, M., Diamond, P., Emond, J., Lemay, M., Candas, B. (1993) Optimized strategy for detection of early stage, curable prostate cancer: role of prescreening with prostate-specific antigen. Clin. Invest. Med., 16: 425-439. |
Prostate Cancer |
1993 |
|
152. Labrie, F., Dupont, A., Suburu, R., Cusan, L., Tremblay, M., Gomez, J.L., Emond, J. (1992) Serum prostate specific antigen (PSA) as prescreening test for prostate cancer. J. Urol., 147: 846-851. |
Prostate Cancer |
1992 |
|
725. Labrie, F., Koutsilieris, M. (2008) The 12th International Congress on Hormonal Steroids and Hormones & Cancer. J Steroid Biochem Mol Biol, 108: 179. |
Prostate Cancer |
2008 |
|
20. Labrie, F., Luu-The, V., Bélanger, A., Lin, S.-X., Simard, J., Pelletier, G., Labrie, C. (2005) Is DHEA a hormone? Starling Review. J Endocrinol, 187: 169-196. |
Prostate Cancer |
2005 |
|
40. Labrie, F., Luu-The, V., Labrie, C., Simard, J. (2001) DHEA and its transformation into androgens and estrogens in peripheral target tissues: Intracrinology. Neuroendocrinologie, 22: 185-212. |
Prostate Cancer |
2001 |
|
50. Labrie, F., Luu-The, V., Lin, S.-X., Simard, J., Labrie, C. (2000) Role of 17beta-hydroxysteroid dehydrogenases in sex steroid formation in peripheral intracrine tissues. Trends Endocrinol. Metab., 11: 421-427. |
Prostate Cancer |
2000 |
|
51. Labrie, F., Luu-The, V., Lin, S.-X., Simard, J., Labrie, C., El-Alfy, M., Pelletier, G., Bélanger, A. (2000) Intracrinology: role of the family of 17beta-hydroxysteroid dehydrogenases in human physiology and disease. J. Mol. Endocrinol., 25: 1-16. |
Prostate Cancer |
2000 |
|
129. Labrie, F., Simard, J., Bélanger, A., Luu-The, V., Labrie, C. (1994) Molecular biology of the intracrine steroidogenic enzymes in the human prostate, in: Motta, M. et Serio, M., eds: Sex Hormones and Antihormones in Endocrine-Dependent Pathology: Basic and Clinical Aspects, New York, Elsevier, pp 77-92. |
Prostate Cancer |
1994 |
|
85. Labrie, F., Simard, J., Candas, B. (1997) Reply by the authors to: Editorial comment of: Comparison of in vitro effects of the pure antiandrogens OH-Flutamide, Casodex and Nilutamide on androgen-sensitive parameters [Reply to the authors/P.F. Schellhammer]. Urology, 49: 586-589. |
Prostate Cancer |
1997 |
|
86. Labrie, F., Simard, J., Singh, S.M., Candas, B. (1997) Estimated potency of Casodex: A problematic design [Letter to the Editor re Schellhammer et al. 45: 745-52, 1995]. Urology, 50: 309-313. |
Prostate Cancer |
1997 |
|
174. Lacoste, D., Bélanger, A., Labrie, F. (1990) Biosynthesis and degradation of androgens in human prostatic cancer cell lines. In: Bradlow, H., Castagnetta, L., d'Aquino, S. et Labrie, F., eds. Steroid Formation, Degradation and Action in Peripheral Tissues Normal and Neoplastic Tissues. Ann. New York Acad. Sci. pp 389-391. |
Prostate Cancer |
1990 |
|
175. Lacoste, D., Candas, B., Normand, M., Labrie, F. (1990) Model of the distribution and metabolism of a GnRH superagonist in dogs. Am. J. Physiol., 258: E468-E475. |
Prostate Cancer |
1990 |
|
87. Laverdiere, J., Gomez, J.L., Cusan, L., Suburu, R.E., Diamond, P., Lemay, M., Candas, B., Fortin, A., Labrie, F. (1997) Beneficial effect of combination therapy administered prior to, during and following external beam radiation therapy in localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys., 37: 247-252. |
Prostate Cancer |
1997 |
|
8. Levesque, M.H., El-Alfy, M., Berger, L., Labrie, F., Labrie, C. (2007) Evaluation of AIbZIP and Cdc47 as Markers for Human Prostatic Diseases. Urology, 69: 196-201. |
Prostate Cancer |
2007 |
|
116. Li, X., Singh, S.M., Côté, J., Laplante, S., Veilleux, R., Labrie, F. (1995) Synthesis and in vitro evaluation of 4-substituted-N-(1,1-dimethylethyl)-3-oxo-4-androsten-17beta-carboxamides as 5alpha-reductase inhibitors and antiendrogens. J. Med. Chem., 38: 1456-1461. |
Prostate Cancer |
1995 |
|
117. Li, X., Singh, S.M., Labrie, F. (1995) Synthesis and in vitro activity of 17beta-(N-alkyl)formamido/ alkylamido-4-aza-/4-methyl-4-aza-3-oxo-5beta-androstan-3-ones as inhibitors of human 5alpha-reductase and antagonists on the androgen receptor. J. Med. Chem., 38: 1158-1173. |
Prostate Cancer |
1995 |
|
118. Li, X., Singh, S.M., Lourdusamy, M., Mérand, Y., Veilleux, R., Labrie, F. (1995) Synthesis and in vitro antiandrogenic activity of 17beta-hydroxy-17beta-(w-hydroxy/haloalkyn-1'-yl)-4-methyl-4-aza-3-oxo-5beta-androstan-(1-ene)-3-ones. Bioorg. Med. Chem. Lett., 5: 1061-1064. |
Prostate Cancer |
1995 |
|
88. Luo, S., Chen, C., Labrie, C., Candas, B., Singh, S.M., Labrie, F. (1997) Daily dosing with Flutamide or Casodex exerts maximal antiandrogenic activity. Urology, 50: 913-919. |
Prostate Cancer |
1997 |
|
105. Luo, S., Martel, C., Leblanc, G., Candas, B., Singh, S.M., Labrie, C., Simard, J., Bélanger, A., Labrie, F. (1996) Relative potencies of flutamide and casodex: preclinical studies. Endocrine-Related Cancer, 3: 229-241. |
Prostate Cancer |
1996 |
|
3. Luu-The, V., Bélanger, A., Labrie, F. (2008) Androgen biosynthetic pathways in the human prostate. Best Pract Res Clin Endocrinol Metab, 22: 207-221. |
Prostate Cancer |
2008 |
|
4687. Ma, C., Yoshioka, M., Boivin, A., Belleau, P., Gan, L., Takase, Y., Labrie, F., St-Amand, J. (2008) Erratum: Prostate specific genes and their regulation by dihydrotestosterone. Prostate, 68: 1372. |
Prostate Cancer |
2008 |
|
4. Ma, C., Yoshioka, M., Boivin, A., Belleau, P., Gan, L., Takase, Y., Labrie, F., St-Amand, J. (2008) Prostate specific genes and their regulation by dihydrotestosterone. Prostate, 68: 241-254. |
Prostate Cancer |
2008 |
|
153. Martel, C., Trudel, C., Couet, J., Labrie, C., Bélanger, A., Labrie, F. (1992) Blockade of androgen action by combined treatment with a pure antiandrogen (Flutamide) and a 5α-reductase inhibitor (4-MA), in: Giuliani, L. et Puppo, P., eds: Urology, Bologna, Monduzzi Editore, pp 605-610. |
Prostate Cancer |
1992 |
|
145. Martel, C., Trudel, C., Couet, J., Labrie, C., Bélanger, A., Labrie, F. (1993) Blockade of androstenedione-induced stimulation of androgen-sensitive parameters in the rat prostate by combination of Flutamide and 4-MA. Mol. Cell. Endocrinol., 91: 43-49. |
Prostate Cancer |
1993 |
|
119. Narod, S., Dupont, A., Cusan, L., Diamond, P., Gomez, J.L., Suburu, R., Labrie, F. (1995) The impact of family history on early detection of prostate cancer. Nature Medicine, 1: 99-101. |
Prostate Cancer |
1995 |
|
146. Normand, T., Narod, S., Labrie, F., Simard, J. (1993) Detection of polymorphisms in the estradiol 17β-hydroxysteroid dehydrogenase II gene at the human EDH17B2 locus on 17q11-q21. Hum. Mol. Genet., 2: 479-483. |
Prostate Cancer |
1993 |
|
52. Pelletier, G., Labrie, C., Labrie, F. (2000) Localization of oestrogen receptor alpha oestrogen receptor beta and androgen receptors in the rat reproductive organs. J. Endocrinol., 165: 359-370. |
Prostate Cancer |
2000 |
|
41. Pelletier, G., Luu-The, V., El Alfy, M., Li, S., Labrie, F. (2001) Immunoelectron microscopic localization of 3beta-hydroxysteroid dehydrogenase and type 5 17beta-hydroxysteroid dehydrogenase in the human prostate and mammary gland. J. Mol. Endocrinol., 26: 11-19. |
Prostate Cancer |
2001 |
|
17. Perreira De Jésus, K., Côté, P.L., Cantin, L., Blanchet, J., Labrie, F., Breton, R. (2006) Comparison of crystal structures of human androgen receptor ligand-binding domain complexed with various agonists reveals molecular determinants responsible for binding affinity. Protein Science: a publication of the Protein Society, 15: 987-99. |
Prostate Cancer |
2006 |
|
176. Pinault, S., Fortin, D., Gagnon, J., Têtu, B., Dupont, A., Labrie, F. (1990) La biopsie prostatique transrectale sous guide ultrasonore. Radiologie, 10: 313-317. |
Prostate Cancer |
1990 |
|
154. Pinault, S., Têtu, B., Gagnon, J., Monfette, G., Dupont, A., Labrie, F. (1992) Transrectal ultrasound evaluation of local prostate cancer in patients treated with LHRH agonist and in combination therapy with flutamide. Urology, 39: 254-261. |
Prostate Cancer |
1992 |
|
53. Prostate Cancer Triallist’ Collaborative Group; (2000) Maximum androgen blockade in advanced prostate cancer: an overvierw of the randomised trials. Lancet, 355: 1491-1498. |
Prostate Cancer |
2000 |
|
28. Qiu, W., Zhou, M., Labrie, F., Lin, S.-X. (2004) Crystal structures of the multi-specific 17beta-hydroxysteroid dehydrogenase type 5: Critical androgen regulation in human peripheral tissues. Mol Endocrinol, 18: 1798-1807. |
Prostate Cancer |
2004 |
|
42. Roach III, M.J., Thrasher, J.B., Blasko, J., Raben, D., Stone, N., Katz, A., Labrie, F. (2001) Prostatectomy, brachytherapy, intensity modulated radiotherapy, hormonal-radiotherapy, salvae cryosurgery and the role of combined hormonal blokade in the treatment of prostate cancer. Reviews in Urology, 3: S49-S58. |
Prostate Cancer |
2001 |
|
177. Rousseau, L., Couture, M., Dupont, A., Labrie, F., Couture, N. (1990) Effect of combined androgen blockade with an LHRH agonist and Flutamide in one severe case of male exhibitionism. Can. J. Psychiatry, 35: 338-341. |
Prostate Cancer |
1990 |
|
9. Roy, J., Breton, R., Martel, C., Labrie, F., Poirier, D. (2007) Chemical synthesis and biological activities of 16alpha-derivatives of 5alpha-androstane-3alpha, 17beta-diol as antiandrogens. Bioorg Med Chem, 15: 3003-3018. |
Prostate Cancer |
2007 |